Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Focusing on the unmet medical needs of patients with rare disorders and their families

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

Pioneering cannabinoid treatments for neuropsychiatric conditions

Latest News

11.12

Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

11.05

Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

10.25

Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

09.26

Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference